K-RAS Mutation Detection Kit

K-RAS Mutation Detection Kit (DsX, Manchester, UK) detects seven key mutations in the K-RAS gene. Recent publications suggest that in lung cancer patients the K-RAS mutation status is a strong predictor of resistance to therapy with tyrosine kinase inhibitors, such as IressaT (AstraZeneca) or TarcevaT (Roche /OSI Pharmaceuticals). The DxS K-RAS mutation detection kit can be used to identify these patients. The kit can also be used to provide biomarker information to companies with therapies in development. These assays employ a real-time PCR format combining Scorpions and ARMSR (allele specific PCR) technologies. As little as <1;% of mutant can be detected in a background of wild type genomic DNA and have a limit of detection of 10 copies or below.